Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12322193 | 0.82 | CNR2 (0.42) | CNR2 | |
| SCHEMBL23123262 | 0.76 | PKM (0.36) | CXCR2MAPT | |
| SCHEMBL2458379 | 0.76 | QDPR (0.38) | CXCR2 | |
| SCHEMBL5661574 | 0.74 | DRD2 (0.30) | — | |
| SCHEMBL2423348 | 0.72 | DRD2 (0.32) | — | |
| SCHEMBL2940758 | 0.72 | DRD2 (0.32) | — | |
| SCHEMBL308840 | 0.72 | BACE1 (0.30) | CXCR2 | |
| SCHEMBL306966 | 0.72 | DRD2 (0.35) | — | |
| SCHEMBL212403 | 0.72 | PDK4 (0.46) | — | |
| SCHEMBL1368155 | 0.71 | LIPE (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CNR2 3546/4885CXCR2 1714/4885MAPT 2392/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CNR2 3546/4885CXCR2 1714/4885MAPT 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.